# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
TD Cowen analyst Dan Brennan initiates coverage on Biodesix (NASDAQ:BDSX) with a Buy rating and announces Price Target of $2.8.
Biodesix (NASDAQ:BDSX) reported quarterly losses of $(0.14) per share which met the analyst consensus estimate. This is a 41.67...
Lake Street initiates coverage on Biodesix (NASDAQ:BDSX) with a Buy rating and announces Price Target of $3.
These presentations highlight advancements in liquid biopsy technologies that detect cell free DNA (cfDNA) and the clinical val...
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 200 points on Friday. The Dow...
Shares of Byrna Technologies Inc. (NASDAQ: BYRN) rose sharply during Friday’s session after the company reported better-than-ex...
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 200 points on Friday. The Dow tr...
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Friday. Following the market openin...